Last year ATH had several papers accepted. Perhaps this time the final version of the 201 study. It starts on the 5th of April. It could also be something else related to brain atrophy.
They have done preclinical studies, but never published anything. An Alzheimer poster or an eye-related poster could help us after this dilution we are getting once again.
They also could have something else to publish in AAN (American Academy of Neurology). In the annual report, they say "To date, we have performed in vivo evaluations of our product candidates in a range of animal models of disease including Parkinsonian disorders, Alzheimer’s disease, Huntington's disease, and brain cancer.
When the possible papers are accepted ATH usually tells it clearly before the congress.
ATH Price at posting:
1.2¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)